Ng Brendan J, Le Couteur David G, Hilmer Sarah N
Faculty of Medicine, University of Sydney, Sydney, NSW, Australia.
Departments of Aged Care and Clinical Pharmacology, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia.
Drugs Aging. 2018 Jun;35(6):493-521. doi: 10.1007/s40266-018-0544-4.
Benzodiazepines (BZDs; including the related Z-drugs) are frequently targets for deprescribing; long-term use in older people is harmful and often not beneficial. BZDs can result in significant harms, including falls, fractures, cognitive impairment, car crashes and a significant financial and legal burden to society. Deprescribing BZDs is problematic due to a complex interaction of drug, patient, physician and systematic barriers, including concern about a potentially distressing but rarely fatal withdrawal syndrome. Multiple studies have trialled interventions to deprescribe BZDs in older people and are discussed in this narrative review. Reported success rates of deprescribing BZD interventions range between 27 and 80%, and this variability can be attributed to heterogeneity of methodological approaches and limited generalisability to cognitively impaired patients. Interventions targeting the patient and/or carer include raising awareness (direct-to-consumer education, minimal interventions, and 'one-off' geriatrician counselling) and resourcing the patient (gradual dose reduction [GDR] with or without cognitive behavioural therapy, teaching relaxation techniques, and sleep hygiene). These are effective if the patient is motivated to cease and is not significantly cognitively impaired. Interventions targeted to physicians include prescribing interventions by audit, algorithm or medication review, and providing supervised GDR in combination with medication substitution. Pharmacists have less frequently been the targets for studies, but have key roles in several multifaceted interventions. Interventions are evaluated according to the Behaviour Change Wheel. Research supports trialling a stepwise approach in the cognitively intact older person, but having a low threshold to use less-consultative methods in patients with dementia. Several resources are available to support deprescribing of BZDs in clinical practice, including online protocols.
苯二氮䓬类药物(BZDs;包括相关的Z类药物)经常成为减药的对象;在老年人中长期使用有害且往往并无益处。BZDs可导致严重危害,包括跌倒、骨折、认知障碍、车祸以及给社会带来巨大的经济和法律负担。由于药物、患者、医生和系统障碍之间的复杂相互作用,BZDs减药存在问题,其中包括对潜在痛苦但很少致命的戒断综合征的担忧。多项研究对老年人停用BZDs的干预措施进行了试验,本叙述性综述对此进行了讨论。报告的停用BZDs干预措施的成功率在27%至80%之间,这种差异可归因于方法学方法的异质性以及对认知障碍患者的普遍适用性有限。针对患者和/或护理人员的干预措施包括提高认识(直接面向消费者的教育、最小干预措施和“一次性”老年病医生咨询)以及为患者提供资源(有或没有认知行为疗法的逐渐减量[GDR]、教授放松技巧和睡眠卫生)。如果患者有意愿停药且认知功能没有明显受损,这些措施是有效的。针对医生的干预措施包括通过审核、算法或药物审查进行处方干预,以及在药物替代的同时提供监督下的GDR。药剂师较少成为研究对象,但在一些多方面干预措施中发挥着关键作用。根据行为改变轮对干预措施进行评估。研究支持在认知功能正常的老年人中尝试逐步方法,但对痴呆症患者使用较少咨询方法的门槛要低。有几种资源可用于支持临床实践中BZDs的减药,包括在线方案。